ADORA2A and Alzheimer disease: Additionally favoring the potential of A2AR antagonist in AD therapy is the reduced activity of N-methyl-D-aspartate receptors (NMDARs), resulting from cross-antagonisms within macromolecular complexes formed by NMDA and A2A receptors in both neurons and microglia [32].